Last reviewed · How we verify
Fludeoxyglucose 18F
Fludeoxyglucose 18F is a Small molecule drug developed by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. It is currently FDA-approved. Also known as: 18-Fludeoxyglucose (18FDG).
At a glance
| Generic name | Fludeoxyglucose 18F |
|---|---|
| Also known as | 18-Fludeoxyglucose (18FDG) |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- DDAVP for Pituitary Adenoma (NA)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1,PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1,PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Reliability of the Human Brain Connectome (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fludeoxyglucose 18F CI brief — competitive landscape report
- Fludeoxyglucose 18F updates RSS · CI watch RSS
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla portfolio CI
Frequently asked questions about Fludeoxyglucose 18F
What is Fludeoxyglucose 18F?
Fludeoxyglucose 18F is a Small molecule drug developed by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla.
Who makes Fludeoxyglucose 18F?
Fludeoxyglucose 18F is developed and marketed by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (see full Fundación Pública Andaluza para la gestión de la Investigación en Sevilla pipeline at /company/fundaci-n-p-blica-andaluza-para-la-gesti-n-de-la-investigaci-n-en-sevilla).
Is Fludeoxyglucose 18F also known as anything else?
Fludeoxyglucose 18F is also known as 18-Fludeoxyglucose (18FDG).
What development phase is Fludeoxyglucose 18F in?
Fludeoxyglucose 18F is FDA-approved (marketed).
Related
- Manufacturer: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full pipeline
- Therapeutic area: All drugs in Metabolic
- Also known as: 18-Fludeoxyglucose (18FDG)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing